GSK plc (BCBA:GSK)
Argentina · Delayed Price · Currency is ARS | Market Cap | 150.29T +62.0% |
| Revenue (ttm) | 59.80T +4.0% |
| Net Income | 10.63T +84.9% |
| EPS | 2,590.57 +86.6% |
| Shares Out | n/a |
| PE Ratio | 14.13 |
| Forward PE | 10.30 |
| Dividend | 548.42 (2.73%) |
| Ex-Dividend Date | May 15, 2026 |
| Volume | n/a |
| Open | 20,460 |
| Previous Close | 20,090 |
| Day's Range | 20,410 - 20,460 |
| 52-Week Range | 11,850 - 22,760 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 28, 2026 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2025, GSK plc's revenue was 32.67 billion, an increase of 4.11% compared to the previous year's 31.38 billion. Earnings were 5.72 billion, an increase of 121.98%.
Financial numbers in GBP Financial StatementsNews
GSK Canada announces approval of Shingrix in prefilled syringe
GSK (GSK) Canada announced the approval of Shingrix in a prefilled syringe. This new presentation removes the need to reconstitute separate vials prior to administration.
GSK Receives Neutral Rating from Citi with 2,100 GBp Price Target
GSK Receives Neutral Rating from Citi with 2,100 GBp Price Target
GSK resumed with a Neutral at Citi
Citi resumed coverage of GSK (GSK) with a Neutral rating and 2,100 GBp price target following the Nuvalent acquisition. The firm views the deal as “sensible” but says GSK has…
FTSE 100 shares to watch: Lloyds, Barclays, IAG, NatWest, GSK, AstraZeneca
The FTSE 100 Index was little changed this week as investors assessed the escalating UK-Iran crisis, the ongoing US earnings season, and a series of key UK economic releases. Market participants diges...
AstraZeneca 'magic' faces rare test after trial failure, share slide
AstraZeneca's long-time CEO Pascal Soriot has rarely put a foot wrong. The company's shares have more that quadrupled in price during his 14-year tenure, soaring above the wider FTSE 100 index and mai...
GSK Wins Early FDA Approval For Jideytro In ROS1-Positive Lung Cancer For Adults
(RTTNews) - GSK plc (GSK) announced that the US Food and Drug Administration (FDA) has approved Jideytro, chemically known as zidesamtinib, for the treatment of adult patients with locally advanced or...
GSK Enters Lung Cancer Therapy Market with FDA Approval of Jideytro
GSK Enters Lung Cancer Therapy Market with FDA Approval of Jideytro
GSK Receives FDA Approval for Jideytro to Treat ROS1-Positive Lung Cancer
GSK Receives FDA Approval for Jideytro to Treat ROS1-Positive Lung Cancer
Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer
Approval based on ARROS-1 phase I/II trial demonstrating meaningful and durable responses in patients with locally advanced or metastatic disease1 Next-generation design aims to address key efficacy a...
GSK reports Jideytro approved by FDA for ROS1-positive NSCLC
GSK (GSK) announced the U.S. Food and Drug Administration has approved Jideytro, a ROS1 selective inhibitor, for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-s...
US FDA approves GSK's lung cancer drug
GSK said on Wednesday the U.S. FDA has approved its drug for adults with a form of lung cancer who have previously received a targeted therapy.
Noteworthy ETF Inflows: FENI, AER, GSK, SE
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Fidelity Enhanced International ETF (Symbol: FENI) where we have detec...
GSK Unveils New Data on Long-Acting HIV Treatments Ahead of AIDS Conference
GSK Unveils New Data on Long-Acting HIV Treatments Ahead of AIDS Conference
GSK’s ViiV Healthcare to present new data on INSTI-focused portfolio
GSK (GSK) announced that ViiV Healthcare announced new clinical and real-world data highlighting its integrase strand transfer inhibitor, INSTI, -focused portfolio, including long-acting medicines and...
ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults; alongside INSTI-powered long-acting injectable innovation at AIDS 2026
LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced new clinical and real-world data highlighting its int...
GSK PLC (GSK) Shares Fall 3.3% -- What GF Score of 69 Tells Investors
GSK PLC (GSK) Shares Fall 3.3% -- What GF Score of 69 Tells Investors
GSK Seeks Booster Approval for Bexsero Vaccine
GSK Seeks Booster Approval for Bexsero Vaccine
GSK announces EMA accepted submission to update Bexsero label
GSK (GSK) announced the European Medicines Agency, EMA, has accepted a submission to update the label for Bexsero to include a single dose booster for individuals aged 10 years and…
Trevi Therapeutics price target raised to $40 from $29 at Clear Street
Clear Street raised the firm’s price target on Trevi Therapeutics (TRVI) to $40 from $29 and keeps a Buy rating on the shares after GSK (GSK) discontinued camlipixant in refractory…
GSK: EMA Accepts Filing For Bexsero Single-Dose Booster In Adolescents
(RTTNews) - GSK plc (GSK) announced that the European Medicines Agency (EMA) has accepted its submission to update the label for Bexsero, aiming to include a single-dose booster for individuals aged 1...
GSK Drops Chronic Cough Drug as Shares Fall 4.5%
GSK Drops Chronic Cough Drug as Shares Fall 4.5%
GSK Shares Decline After Camlipixant Trial Setback
GSK Shares Decline After Camlipixant Trial Setback
GSK Shares Slide After Drugmaker Drops Chronic Cough Treatment
GSK shares fell after the U.K. drugmaker said it would stop working on an experimental treatment for chronic cough after mixed results showed limited efficacy in late-stage clinical studies.
GSK Ceases Phase 3 Development Of Camlipixant In Chronic Cough, Advances Drug For IBS
(RTTNews) - GSK plc (GSK), a biopharmaceutical company, on Friday announced the discontinuation of Phase 3 development for Camlipixant in treating refractory chronic cough (RCC).
GSK: Clinical Trials Update on Camlipixant for Chronic Cough
GSK: Clinical Trials Update on Camlipixant for Chronic Cough